Literature DB >> 24163265

Menstrual cycle characteristics in fertile women from Greenland, Poland and Ukraine exposed to perfluorinated chemicals: a cross-sectional study.

J Lyngsø1, C H Ramlau-Hansen, B B Høyer, H Støvring, J P Bonde, B A G Jönsson, C H Lindh, H S Pedersen, J K Ludwicki, V Zviezdai, G Toft.   

Abstract

STUDY QUESTION: Does perfluorooctane sulfonate (PFOS) and perfluorooctanate (PFOA) exposure disrupt the menstrual cyclicity? SUMMARY ANSWER: The female reproductive system may be sensitive to PFOA exposure, with longer menstrual cycle length at higher exposure. WHAT IS KNOWN ALREADY: PFOS and PFOA are persistent man-made chemicals. Experimental animal studies suggest they are reproductive toxicants but epidemiological findings are inconsistent. STUDY DESIGN, SIZE, DURATION: A cross-sectional study including 1623 pregnant women from the INUENDO cohort enrolled during antenatal care visits between June 2002 and May 2004 in Greenland, Poland and Ukraine. PARTICIPANTS/MATERIALS, SETTING,
METHODS: Information on menstrual cycle characteristics was obtained by questionnaires together with a blood sample from each pregnant woman. Serum concentrations of PFOS and PFOA were measured by liquid chromatography tandem mass spectrometry. Multiple imputations were performed to account for missing data. The association between PFOS/PFOA and menstrual cycle length (short cycle: ≤24 days, long cycle: ≥32 days) and irregularities (≥7 days in difference between cycles) was analyzed using logistic regression with tertiles of exposure. Estimates are given as adjusted odds ratios (ORs) with 95% confidence intervals (CIs). MAIN RESULTS AND THE ROLE OF CHANCE: Higher exposure levels of PFOA were associated with longer menstrual cycles in pooled estimates of all three countries. Compared with women in the lowest exposure tertile, the adjusted OR of long cycles was 1.8 (95% CI: 1.0; 3.3) among women in the highest tertile of PFOA exposure. No significant associations were observed between PFOS exposure and menstrual cycle characteristics. However, we observed a tendency toward more irregular cycles with higher exposure to PFOS [OR 1.7 (95% CI: 0.8; 3.5)]. The overall response rate was 45.3% with considerable variation between countries (91.3% in Greenland, 69.1% in Poland and 26.3% in Ukraine). LIMITATIONS, REASONS FOR CAUTION: Possible limitations in our study include varying participation rates across countries; a selected study group overrepresenting the most fertile part of the population; retrospective information on menstrual cycle characteristics; the determination of cut-points for all three outcome variables; and lacking information on some determinants of menstrual cycle characteristics, such as stress, physical activity, chronic diseases and gynecological disorders, thus confounding cannot be excluded. WIDER IMPLICATIONS OF THE
FINDINGS: The generalizability of the study results is restricted to fertile women who manage to conceive and women who do not use oral contraceptives when getting pregnant or within 2 months before getting pregnant. To our knowledge only one previous epidemiological study has addressed the possible association between perfluorinated chemical exposure and menstrual disturbances. Though pointing toward different disturbances in cyclicity, both studies suggest that exposure to PFOA may affect the female reproductive function. This study contributes to the limited knowledge on effects of exposure to PFOA and PFOS on female reproductive function and suggests that the female reproductive system may be affected by environmental exposure to PFOA. STUDY FUNDING/COMPETING INTEREST(S): Supported by a scholarship from Aarhus University Research Foundation. The collection of questionnaire data and blood samples was part of the INUENDO project supported by The European Commission (Contract no. QLK4-CT-2001-00 202), www.inuendo.dk. The Ukrainian part of the study was possible by a grant from INTAS (project 012 2205). Determination of PFOA and PFOS in serum was part of the CLEAR study (www.inuendo.dk/clear) supported by the European Commission's 7th Framework Program (FP7-ENV-2008-1-226217). No conflict of interest declared.

Entities:  

Keywords:  PFOA; PFOS; menstrual cycle

Mesh:

Substances:

Year:  2013        PMID: 24163265     DOI: 10.1093/humrep/det390

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  15 in total

1.  Perfluoroalkyl and polyfluoroalkyl substances (PFAS) and their effects on the ovary.

Authors:  Ning Ding; Siobán D Harlow; John F Randolph; Rita Loch-Caruso; Sung Kyun Park
Journal:  Hum Reprod Update       Date:  2020-09-01       Impact factor: 15.610

2.  Windows of sensitivity to toxic chemicals in the development of reproductive effects: an analysis of ATSDR's toxicological profile database.

Authors:  Melanie C Buser; Henry G Abadin; John L Irwin; Hana R Pohl
Journal:  Int J Environ Health Res       Date:  2018-07-19       Impact factor: 3.411

3.  Oral contraceptive use as a determinant of plasma concentrations of perfluoroalkyl substances among women in the Norwegian Mother and Child Cohort (MoBa) study.

Authors:  Elise L Rush; Alison B Singer; Matthew P Longnecker; Line S Haug; Azemira Sabaredzovic; Elaine Symanski; Kristina W Whitworth
Journal:  Environ Int       Date:  2017-12-20       Impact factor: 9.621

4.  Longitudinal trends in perfluoroalkyl and polyfluoroalkyl substances among multiethnic midlife women from 1999 to 2011: The Study of Women's Health Across the Nation.

Authors:  Ning Ding; Siobán D Harlow; Stuart Batterman; Bhramar Mukherjee; Sung Kyun Park
Journal:  Environ Int       Date:  2019-12-13       Impact factor: 9.621

5.  Perfluoroalkyl substances and ovarian hormone concentrations in naturally cycling women.

Authors:  Emily S Barrett; Chongshu Chen; Sally W Thurston; Line Småstuen Haug; Azemira Sabaredzovic; Frøydis Nyborg Fjeldheim; Hanne Frydenberg; Susan F Lipson; Peter T Ellison; Inger Thune
Journal:  Fertil Steril       Date:  2015-03-04       Impact factor: 7.329

Review 6.  An Epidemiologic Review of Menstrual Blood Loss as an Excretion Route for Per- and Polyfluoroalkyl Substances.

Authors:  Kristen Upson; Jenni A Shearston; Marianthi-Anna Kioumourtzoglou
Journal:  Curr Environ Health Rep       Date:  2022-03-10

Review 7.  Per- and poly-fluoroalkyl substances (PFAS) and female reproductive outcomes: PFAS elimination, endocrine-mediated effects, and disease.

Authors:  Brittany P Rickard; Imran Rizvi; Suzanne E Fenton
Journal:  Toxicology       Date:  2021-11-10       Impact factor: 4.571

8.  Perfluoroalkyl Chemicals, Menstrual Cycle Length, and Fecundity: Findings from a Prospective Pregnancy Study.

Authors:  Kirsten J Lum; Rajeshwari Sundaram; Dana B Barr; Thomas A Louis; Germaine M Buck Louis
Journal:  Epidemiology       Date:  2017-01       Impact factor: 4.822

9.  Perfluoroalkyl substances and time to pregnancy in couples from Greenland, Poland and Ukraine.

Authors:  Kristian T Jørgensen; Ina O Specht; Virissa Lenters; Cathrine C Bach; Lars Rylander; Bo A G Jönsson; Christian H Lindh; Aleksander Giwercman; Dick Heederik; Gunnar Toft; Jens Peter Bonde
Journal:  Environ Health       Date:  2014-12-22       Impact factor: 5.984

10.  Changes in serum concentrations of maternal poly- and perfluoroalkyl substances over the course of pregnancy and predictors of exposure in a multiethnic cohort of Cincinnati, Ohio pregnant women during 2003-2006.

Authors:  Kayoko Kato; Lee-Yang Wong; Aimin Chen; Carmen Dunbar; Glenys M Webster; Bruce P Lanphear; Antonia M Calafat
Journal:  Environ Sci Technol       Date:  2014-07-29       Impact factor: 9.028

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.